secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2024-06-12T23:59:59+00:00
Accession:  0001193125-24-159393
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Setrusumab Phase 2 data: 67% fracture rate reduction in OI at 14 months
-----------------------------------------------------------------------

- Median annualized fracture rate reduced 67% to 0.00 (p=0.0014, n=24) vs pre-treatment 0.72.
- Lumbar spine BMD increased mean 22% at 12 months (p<0.0001, n=19); Z-score improved +1.25 (p<0.0001, n=18).
- No treatment-related serious adverse events or hypersensitivity reactions reported.
- Phase 3 Orbit (158 patients) and Cosmic (69 patients) studies fully enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524159393/0001193125-24-159393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524159393/d849907d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-159393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer